• Cartherics’ Deputy Chair, Prof. Alan Trounson AO will be presenting at ISSCR 2025 on Friday 12^th December, 2025 at 3.25pm (US EST)

Melbourne, Australia, 8 December 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is pleased to announce that Prof. Alan Trounson AO, Deputy Chair, will present at the International Society for Stem Cell Research (ISSCR) International Symposium, 11-12 December 2025 in Boston, USA.

At this leading global forum for stem cell and regenerative medicine innovation, Cartherics will join experts from around the world to share new advances and contribute to accelerating progress of pluripotent stem cell-derived cell therapies into clinical trials.

Prof. Trounson’s presentation, titled, Allogeneic iPSC-Derived CAR-NK Cells Targeting Ovarian Cancer, will take place on Friday 12^th December, 2025 at 3.25pm and will share its latest research on the Company’s lead product, CTH-401, an allogeneic, gene-modified, induced pluripotent stem cell (iPSC)-derived TAG-72 CAR-iNK cell product with DGK gene knockouts (KOs), designed to target ovarian cancer.

Built on Cartherics’ iPSC platform, CTH-401 offers the potential for limitless, standardised, cell therapy production for on-demand supply to patients, with the prospect of reducing or eliminating treatment-associated toxicities common in autologous CAR-T cell approaches.

CTH-401 is the only NK cell product currently in development with DGK genes knocked out (KO) and a CAR targeting TAG-72, a tumor-associated antigen that is expressed on many adenocarcinomas, including around 90% of ovarian cancers. Cartherics plans to submit an IND application for CTH-401 in mid-2026, with the initial clinical indication being relapsed and refractory ovarian cancer followed by other TAG-72 postive adenocarcinomas. The Company is advancing its mission to transform women’s health through a growing pipeline of innovative off-the-shelf immunotherapies for cancer and endometriosis.

Cartherics’ Deputy Chair, Prof. Alan Trounson commented: “IPSCs provide an ideal platform for the clonal derivation of safely gene edited immune cell products that can be rapidly produced in large numbers and assessed for anti-cancer efficacy.”

Cartherics looks forward to engaging with the international stem cell community in Boston and sharing updates on the advancement of allogeneic, iPSC-derived cell therapies.

 

******

 

About Cartherics

Cartherics Pty Ltd is a privately held biotechnology company based in Melbourne, Australia developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis. The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system.  The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells.  The Company’s lead product, CTH-401, is a CAR-iNK cell product.  It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression.  The company has a strong pipeline of additional novel CAR-immune cell products tailored to disrupt a variety of cancers including; ovarian, triple negative breast cancer and other solid tumours; and is also targeting severe endometriosis and neurological diseases with specific NK cell products.

https://cartherics.com/

Watch our latest company video here: https://www.youtube.com/watch?v=rxQEyx6i7hk

 

 

Media contact

Christine Filippis

Teraze Communications

Phone: +61 419 119 866

Email: christine@teraze.com.au